Used in scans for known or suspected focal liver disease. Sold as Eovist. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Gadoxetate Disodium (sold as Eovist), first approved Jul 3, 2008, with 1 new use approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Eovist | Part B | $1.4M | +10% | 8,324 |
| Comparison of ultraSound, Abbreviated MRI witH and Without HBP aS mOdalities for HCC suRveillance in patienTs With High RiskHepatocellular Carcinoma (HCC), Magnetic Resonance Imaging (MRI) · Peking University People's Hospital | Not applicable | Not yet recruiting | Jun 8, 2025 |
| Pharmacologic Approaches to Preventing Primary Sclerosing Cholangitis Recurrence After Liver TransplantationPrimary Sclerosing Cholangitis, Liver Transplant, Complications · Mayo Clinic | Phase 2 | Recruiting | Apr 1, 2025 |
| Gadopiclenol vs Gadoxetate MRI for Liver LesionsLiver Lesion · Icahn School of Medicine at Mount Sinai | — | Enrolling by invitation | Sep 19, 2024 |
| Gadoxetate Abbreviated MRI in Metastatic Colorectal CancerLiver Metastasis Colon Cancer · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Not applicable | Recruiting | Apr 6, 2022 |
| Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 YearsMotor Function, Cognitive Function · Guerbet | Phase 4 | Recruiting | May 4, 2020 |
| Contrast-enhanced MRI in Detecting Benign and Malignant Liver LesionsHepatocellular Carcinoma, Liver and Intrahepatic Bile Duct Disorder · M.D. Anderson Cancer Center | Not applicable | Active, not recruiting | Jun 5, 2014 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Jul 3, 2008 | EovistNDA 22090 · New molecular entity | Bayer Hlthcare | 18 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Bayer Hlthcare